[The effect of prindolol on the blood-pressure profile of hypertensives (with special consideration of response to exercise and plasma-renin activity) (author's transl)].
Using microcatheter blood pressure telemetry, the pressure-lowering effect of prindolol (Visken), a beta-blocking drug, was tested at a dose of 10 mg three time daily by mouth in eight patients with essential hypertension (WHO stage II) and low to normal plasma-renin activities. After about ten days of treatment, the hypertensive reaction to everyday physical exercise (walking, climbing stairs, bicycle ergometry) was especially favourably affected. The average blood-pressure reduction at rest was 18.6/12.1 (systolic/diastolic), on stair climbing 41.5/17.2 mm Hg.
D000328:Adult; D001794:Blood Pressure / Q000187:drug effects*; D002404:Catheterization; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D005082:Physical Exertion; D010869:Pindolol / Q000494:pharmacology* / Q000627:therapeutic use; D012083:Renin / Q000097:blood; D013686:Telemetry; D013997:Time Factors
D010869:Pindolol; D012083:Renin
Beeinflussung des Blutdruckprofils Hochdruckkranker durch Prindolol. Unter besonderer Berücksichtigung der Belastungsreaktion und der Plasmareninaktivität